FDA Panel Supports J&J’s Antibiotic Doribax With Votes, Not Confidence

An FDA panel's votes on July 16 to support Johnson & Johnson's Doribax (doripenem) reflected more the difficulty of new antibiotic drug development than the merits of J&J's particular application